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Acute promyelocytic leukaemia (APML) is a condition classi-
cally characterised by t(15;17) (q22, q21), with disseminated
intravascular coagulopathy (DIC) being a major cause of death.
Central nervous system (CNS) involvement with APML
commonly occurs in relapse; however, it is rarely seen at
presentation, with only six reported cases in the literature. This
case is the ﬁrst to describe a patient with APML who presented
with a subarachnoid haemorrhage and had CNS involvement
early at diagnosis.
A 65-year-old woman was admitted with headache, general-
ised bruising and DIC. Her blood ﬁlm and bone marrow
examination were consistent with classic APML, while MRI scan
conﬁrmed a sub-arachnoid haemorrhage. Consequently she was
commenced on all-trans retinoic acid (ATRA), idarubicin and
aggressive blood product support.
Her treatment was initially complicated by ATRA differentia-
tion syndrome and then extensive pulmonary emboli causing
hypoxia, resulting in commencement of unfractionated heparin
while maintaining a platelet count 45010
9/l.
During her induction she underwent serial MRI scans that,
although conﬁrmed no extension of her subarachnoid
haemorrhage, showed persistent abnormal meningeal thicken-
ing. Lumbar puncture revealed an inﬁltrate of immature granular
leucocytes and CNS involvement was conﬁrmed by both
immunophenotyping and cytogenetic analysis via ﬂuorescent
in situ hybridisation (FISH) (Figure 1). Consequently she went on
to have six cycles of triple intrathecal therapy with methotrex-
ate, cytarabine and hydrocortisone until her cerebrospinal ﬂuid
was clear of leukaemic cells, as conﬁrmed by immunopheno-
typing and FISH.
Bone marrow examination post induction conﬁrmed
complete morphological and cytogenetic remission, at which
point she was commenced on arsenic trioxide and ATRA for
her subsequent consolidation and currently she remains in
remission.
Acute promyelocytic leukaemia is frequently associated with
clotting abnormalities and carries a high risk of intracranial
haemorrhage.
1 Bleeding involving the CNS is often catastrophic
and is the main cause of death in induction for APML.
1–4
CNS involvement in APML is extremely rare at presentation
but not infrequent at relapse, and associated factors include
raised white cell count (41010
9/l), prior CNS haemorrhage,
microgranular variant and bcr3 PML/RARa type.
5,6 Currently
lumbar puncture is not carried out during induction when the
risk of haemorrhagic complications is high. Instead it is reserved
for patients with neurological symptoms or on relapse if CNS
involvement is suspected.
7 Some strategies have included CNS
prophylaxis in patients with high-risk features, although the
beneﬁt from this as yet remains to be established. An Italian
report describes the use of routine lumbar puncture at the end of
induction in newly diagnosed APML patients with a white cell
count 41010
9/l. Seven patients underwent lumbar punctures
and two were identiﬁed with CNS involvement;
6 both of these
patients were in molecular remission in their marrows. The
authors concluded that routine lumbar puncture may be
recommended for patients with high risk features in order to
identify occult CNS disease.
Our case supports that high-risk patients, in particular those
who have intracranial haemorrhage and high white cell count
(41010
9/l) at presentation, should have diagnostic lumbar
puncture performed earlier once the coagulopathy has resolved.
This approach may allow earlier detection and treatment of
occult CNS disease and consequently reduce the risk of future
relapse.
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